BioSpace News Archive

ThermoGenesis Holdings, Inc. today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.

Osivax announced that it has received a global pneumonia and pandemic preparedness grant of over USD 1M from the Bill & Melinda Gates Foundation to support additional research and development of its lead, broad-spectrum influenza vaccine candidate, OVX836.

Salubris Biotherapeutics, Inc. announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

Evotec SE announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016.

Salipro Biotech announces the publication of results from a collaboration with AstraZeneca.

Sirnaomics Ltd. has announced its audited annual results for the year ended 31 December 2022 (the “Year”).

ANANDA Scientific Inc. today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).

Elucid, Inc. has hired Andrew Miller as its chief technology officer (CTO).

Radiopharm Theranostics is pleased to announce that the Company will participate in Jefferies Inaugural Radiopharma Innovation Summit being held in New York City on April 3rd, 2023.

HMNC Brain Health together with Develco Pharma, announced that the last patient has been randomized in its proof-of-concept Phase II clinical trial of ‘Ketabon’, an oral prolonged-release ketamine formulation for Treatment-Resistant Depression.